DUBLIN--(BUSINESS WIRE)--
ICON
plc, (NASDAQ: ICLR) global provider of drug development
solutions and services to the pharmaceutical, biotechnology and medical
device industries, today announced the appointment of Mr. Eugene McCague
as a non-executive director.
Mr. McCague was a corporate partner of Arthur Cox, one of Ireland's
premier law firms, from 1988 until June 2017. During his time with
Arthur Cox, Mr. McCague served as both managing partner and chairman of
Arthur Cox and also advised a wide range of public and private companies
on mainstream corporate work, mergers and acquisitions, corporate
restructurings and corporate governance.
In addition to his distinguished legal career, Mr. McCague also has
extensive board experience with commercial, government and educational
organizations. Mr. McCague currently serves on the board of FLY Leasing
Limited, an aircraft leasing company listed on the New York Stock
Exchange, and on the board of the Irish branch of AON Insurance. He also
serves as chairman of the governing authority of University College
Dublin.
Mr. McCague's previous board roles include the Health Service Executive,
the Irish state body which administers public health service in Ireland,
chairman of the governing body of Dublin Institute of Technology and
chairman of the Dublin Institute of Technology Foundation. Mr. McCague
was also president of the Dublin Chamber of Commerce in 2006.
Mr. McCague holds a Bachelor of Civil Law degree and a diploma in
European Law from University College Dublin.
"I am very pleased that Eugene has joined the board,"
commented Mr. Ciaran Murray, Chairman of the Board. "His leadership
positions at Arthur Cox, one of Ireland's premier law firms, and his
strong business experience across many industry sectors will bring
invaluable expertise to the ICON board."
About ICON plc
ICON plc is a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 97 locations in 38 countries and
has approximately 13,100 employees.
Further information is available at www.iconplc.com.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at http://www.sec.gov.
ICON/ICLR-F
View source version on businesswire.com: http://www.businesswire.com/news/home/20171004005577/en/
ICON
Investor Relations
1-888-381-7923
or
Brendan
Brennan Chief Financial Officer
+ 353 -1-291-2000
or
Jonathan
Curtain Vice President Corporate Finance & Investor Relations
+1-215-616-3000
Source: ICON plc
News Provided by Acquire Media
